- Home
- JL vs IBIO Comparison
JL vs IBIO Comparison
Compare JL & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- IBIO
- Stock Information
- Founded
- JL 1985
- IBIO 2008
- Country
- JL Hong Kong
- IBIO United States
- Employees
- JL N/A
- IBIO N/A
- Industry
- JL
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- JL
- IBIO Health Care
- Exchange
- JL NYSE
- IBIO Nasdaq
- Market Cap
- JL 10.0M
- IBIO 9.3M
- IPO Year
- JL 2024
- IBIO N/A
- Fundamental
- Price
- JL $3.90
- IBIO $0.73
- Analyst Decision
- JL
- IBIO Strong Buy
- Analyst Count
- JL 0
- IBIO 3
- Target Price
- JL N/A
- IBIO $4.87
- AVG Volume (30 Days)
- JL 19.2K
- IBIO 2.3M
- Earning Date
- JL 05-23-2025
- IBIO 05-02-2025
- Dividend Yield
- JL N/A
- IBIO N/A
- EPS Growth
- JL N/A
- IBIO N/A
- EPS
- JL 0.54
- IBIO N/A
- Revenue
- JL $32,831,195.00
- IBIO $375,000.00
- Revenue This Year
- JL N/A
- IBIO $36.00
- Revenue Next Year
- JL N/A
- IBIO N/A
- P/E Ratio
- JL $7.55
- IBIO N/A
- Revenue Growth
- JL 7.72
- IBIO 650.00
- 52 Week Low
- JL $0.23
- IBIO $0.64
- 52 Week High
- JL $13.41
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- JL 61.21
- IBIO 24.07
- Support Level
- JL $3.10
- IBIO $0.75
- Resistance Level
- JL $4.20
- IBIO $0.82
- Average True Range (ATR)
- JL 0.24
- IBIO 0.14
- MACD
- JL 0.12
- IBIO 0.10
- Stochastic Oscillator
- JL 74.96
- IBIO 3.04
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.